/
CATX
$3.55+$0.51 (+16.78%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$346.7M
114M shares
52-week range
$1.96 – $6.16
38% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
0.30%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-0.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $9.7M | $10.1M | $10.8M | $7.1M | $1.4M | $1.5M | $0 |
| Cost of revenue | $4.3M | $4.6M | $4.9M | $6.2M | $5.5M | $0 | $0 | $0 |
| Gross profit | $3.0M | $5.1M | $5.1M | $4.6M | $1.6M | $1.4M | −$852.0K | $0 |
| Gross margin | 41.7% | 52.9% | 50.9% | 42.8% | 23.0% | 100.0% | -58.6% | — |
| R&D | $1.5M | $1.1M | $1.4M | $2.6M | $2.6M | $21.3M | $41.6M | $84.2M |
| Operating income | −$5.3M | −$3.5M | −$3.4M | −$7.4M | −$15.2M | −$40.9M | $10.5M | −$113.6M |
| EBITDA | −$5.1M | −$3.5M | −$3.4M | −$7.4M | −$14.8M | −$40.0M | $10.5M | −$100.8M |
| Net income | −$4.8M | −$3.3M | −$3.2M | −$7.2M | −$14.7M | −$46.5M | −$79.3M | −$103.1M |
| Net margin | -66.3% | -33.8% | -31.7% | -66.3% | -206.5% | -3243.2% | -5452.5% | — |
| EPS (diluted) | -0.07 | -0.05 | -0.06 | -0.13 | -0.27 | -0.85 | -1.23 | -1.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $397028 | $-1.10 | $-1.26–$-0.87 | 10 |
| 2027 | $448699 | $-1.10 | $-1.45–$-0.78 | 7 |
| 2028 | $15M | $-1.02 | $-1.29–$-0.70 | 9 |
| 2029 | $249M | $-0.21 | $-0.31–$-0.14 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.14
Price
$3.55
Implied downside
-96%
Peer comparison
Perspective Therapeutics, Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
www.perspectivetherapeutics.com- Employees
- 166
- IPO / List date
- Dec 29, 2003
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds CATX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 352,493 | $969.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-06-17 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded CATX yet.
